Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting

Authors:
  • NANiels Andreasen
    Niels Andreasen
  • SESture Eriksson
    Sture Eriksson
  • SBStellan Båtsman
    Stellan Båtsman
  • BNBirgitta Näsman
    Birgitta Näsman
  • LKLena Kilander
    Lena Kilander
  • MGMikaela Grut
    Mikaela Grut
  • MRMarie Rydén
    Marie Rydén
  • AWAnders Wallin
    Anders Wallin
  • MJMikael Jonsson
    Mikael Jonsson
  • HOHasse Olofsson
    Hasse Olofsson

Abstract
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer’s disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0–4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4–10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points; 95% CI, 14.5–16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting.

This publication has 39 references indexed in Scilit: